Compare COLM & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COLM | IRON |
|---|---|---|
| Founded | 1938 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.3B |
| IPO Year | 1997 | 2020 |
| Metric | COLM | IRON |
|---|---|---|
| Price | $55.24 | $59.06 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 11 |
| Target Price | $60.86 | ★ $103.18 |
| AVG Volume (30 Days) | 484.2K | ★ 520.9K |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.17% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 3.24 | N/A |
| Revenue | ★ $3,042,478,000.00 | N/A |
| Revenue This Year | $3.73 | N/A |
| Revenue Next Year | $3.04 | $283.52 |
| P/E Ratio | $17.10 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $47.48 | $30.82 |
| 52 Week High | $77.97 | $99.50 |
| Indicator | COLM | IRON |
|---|---|---|
| Relative Strength Index (RSI) | 36.97 | 39.24 |
| Support Level | $53.96 | $57.81 |
| Resistance Level | $58.08 | $64.00 |
| Average True Range (ATR) | 1.52 | 2.81 |
| MACD | -0.34 | 0.08 |
| Stochastic Oscillator | 17.17 | 16.99 |
Columbia Sportswear Co makes outdoor and active-lifestyle apparel, footwear, equipment, and accessories that it sells under four primary brands: Columbia, Sorel, Mountain Hardwear, and prAna. The majority of sales are in the United States, but the company also has remarkable sales in its three other geographic segments: Latin American and Asia-Pacific; Europe, Middle East, and Africa; and Canada. The majority of sales are through wholesale channels, including sporting goods and department stores, but the company also operates its own branded stores in each of its geographic segments. It sources products from around the world and uses contract manufacturers outside the United States, predominantly in Asia to manufacture its various products.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.